Intensity Therapeutics Inc. Common stock INTS Open Intensity Therapeutics Inc. Common stock in new tab
Intensity Therapeutics Inc. Common stock Analysis (INTS)
Is Intensity Therapeutics Inc. Common stock a good investment? Intensity Therapeutics Inc. Common stock (INTS) is currently trading at 4.58 USD. Market analysts have a consensus price target of 41.50 USD. This suggests a potential upside from current levels.
Earnings Schedule: Intensity Therapeutics Inc. Common stock is expected to release its next earnings report on Aug. 6, 2026. The market consensus estimate for Forward EPS is -2.70.
Investor FAQ
Does Intensity Therapeutics Inc. Common stock pay a dividend?
No, it does not currently pay a dividend.
What asset class is Intensity Therapeutics Inc. Common stock?
Intensity Therapeutics Inc. Common stock is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Aug. 6, 2026. The company currently has a trailing EPS of -4.01.
Company Profile
Intensity Therapeutics, Inc., a late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer relapse and metastasis in the United States. Its lead product candidate includes INT230-6, which is in Phase 3 clinical studies for the treatment of soft tissue sarcoma; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials. The company was incorporated in 2012 and is headquartered in Shelton, Connecticut.
Dividends
Historical Split Corporate Actions
| Split Date | Split Ratio to 1 |
|---|---|
| Feb. 19, 2026 | 0.040000 |
Explore Premium Features
Unlock detailed news and exclusive insights with our Premium subscription.
See Pricing Plans
Community Discussion